TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese~* No clinical evidence of gross genital lesion suggesting sexually-transmitted disease and no clinically present external genital warts~* Other inclusion criteria will be discussed with the investigator during screening~Exclusion Criteria:~* History of known prior vaccination with an HPV vaccine or plans to receive one outside the study~* History of external genital warts~* History of severe allergic reaction that required medical intervention~* Received immune globulin or blood-derived products in the past 6 months or plan to receive any before Month 7 of the study~* History of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, Human Immunodeficiency Virus (HIV), lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition~* Received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids and certain regimens of systemic corticosteroids~* Known thrombocytopenia or coagulation disorder that would contraindicate intramuscular injections~* Ongoing alcohol or drug abuse within the past 12 months

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- V501 (Type: EXPERIMENTAL): Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescents or adults with diagnosis of congenital or juvenile-onset type 1 myotonic dystrophy (DM-1)~* Diagnosis must be genetically confirmed~* Subjects must be male or female aged 12 years to 45 years~* Subjects must have a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at Screening and Run-in (V2)~* Subjects must be ambulatory and able to complete the 10 metre walk/run test (splints allowed)~* Subject's legally authorized representative (LAR) must provide written informed consent and there must be written consent or assent (as age applicable and developmentally appropriate) by the subject before any study-related procedures are conducted~Exclusion Criteria:~* Non-ambulatory (full time) wheel chair user~* Receiving stimulant medication~* Receiving other medications/therapies not stable (changed) within 4 weeks prior to Run-in (V2)~* Medical illness or other concern which would cause investigator to conclude subjects will not be able to perform the study procedures or assessments or would confound interpretation of data obtained during assessment.~* Current enrolment in a clinical trial of an investigational drug or enrolment in a clinical trial of an investigational drug in the last 6 months~* Women of child bearing potential who are pregnant, lactating or not willing to use a protocol defined acceptable contraception method if sexually active and not surgically sterile.~* Gastrointestinal disease which may interfere with the absorption, distribution, metabolism or excretion of the study medication and impact the interpretability of the study results~* Current clinically significant (as determined by the investigator) cardiovascular, renal, hepatic, endocrine or respiratory disease~* Clinically significant heart disease (in the opinion of the investigator) or second or third degree heart block, atrial flutter, atrial fibrillation, ventricular arrhythmias, or is receiving medication for treatment of a cardiac arrhythmia~* A history of chronic liver disease with current out of range values for Alanine transaminase (ALT), clinically relevant hepatic steatosis or other clinical manifestations of ongoing liver disease~* A history of significant drug allergy (such as Steven-Johnson syndrome, anaphylaxis)~* A history of alcohol or substance use disorders

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - Tideglusib (Type: EXPERIMENTAL): 1000 mg tideglusib, orally, once daily
- Cohort 2 - Tideglusib (Type: EXPERIMENTAL): 400 mg tideglusib, orally, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment.~Exclusion Criteria:~* Previous enrollment in another Allergan Bimatoprost SR Study~* Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye~* Anticipated need for laser eye surgery within the first 52 weeks of the study duration~* History of glaucoma surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimatoprost SR 15 μg (Type: EXPERIMENTAL): Study Eye: bimatoprost sustained-release (SR) 15 micrograms (μg) administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
- Bimatoprost SR 10 μg (Type: EXPERIMENTAL): Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
- Timolol 0.5%: Comparator (Type: ACTIVE_COMPARATOR): Both Eyes: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CP-690-550 Ointment For Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate chronic plaque psoriasis (psoriasis vulgaris), with the duration of at least 6 months;~* A target plaque of at least 9 sq. cm.~Exclusion Criteria:~* Demonstrates rebound or flare of chronic plaque psoriasis;~* Non plaque form of psoriasis;~* Currently have or history of psoriatic arthritis;~* Current drug induced psoriasis;~* Currently on systemic therapy or was on systemic therapy for psoriasis within the previous 6 months;~* Currently on phototherapy for psoriasis or was on phototherapy within the previous 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group A (Type: EXPERIMENTAL): None
- Treatment Group B (Type: PLACEBO_COMPARATOR): None
- Treatment Group C (Type: EXPERIMENTAL): None
- Treatment Group D (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age above or equal to 18 years at the time of signing informed consent.~* Body mass index (BMI) greater than or equal to 30.0 kg/m\^2~* New York Heart Association (NYHA) Class II-IV~* Left ventricular ejection fraction (LVEF) greater than or equal to 45 percentage at screening~Exclusion Criteria:~* A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records~* Haemoglobin A1c (HbA1c) greater than or equal to 6.5 percentage (48 mmol/mol) based on latest available value from medical records, no older than 3 months or if unavailable a local measurement at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.
- Placebo (semaglutide) (Type: PLACEBO_COMPARATOR): All participants will receive either semaglutide 2.4 mg once weekly or placebo once weekly as add-on to standard of care. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Montelukast on Remodelling Markers in Asthmatic Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic criteria: the classification of asthma will be based on clinical history and examination and pulmonary function parameters, according to international guidelines.~* Stage and/or severity of condition: atopic children with mild intermittent asthma will be enrolled. Atopy will be evaluated by skin-prick test to common allergens in the area.~* Confirmatory physical and laboratory findings:~* Age: ranging in age 6 to 14 years.~* Evidence of susceptibility to the disease under study~* Patients have not used ICS during 3-month period prior to study entry~Exclusion Criteria:~* Patients will be excluded if they had used oral steroids in the last month.~* Patients will be excluded if they had acute or chronic lung diseases other than asthma, upper or lower airway infection in the previous 3 weeks or during the trial, acute asthma exacerbation, or had used oral steroids in the last month.~* Patients will be excluded if they had acute or chronic lung diseases other than asthma, upper or lower airway infections in the previous 3 weeks or during the trial, acute asthma exacerbation, or had used oral steroids in the last month.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: ACTIVE_COMPARATOR): Montelukast chewing tablets once daily per os, plus inhaled short acting beta2 agonist as needed
- placebo (Type: PLACEBO_COMPARATOR): placebo chewing tablets per os once daily, plus inhaled short acting beta 2 agonist as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Posterior Nasal Nerve (PNN) Rhinitis Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 22 to 75 years (inclusively)~2. Willing and able to provide informed consent~3. Willing and able to comply with the subject-specific requirements outlined in the study protocol~4. Seeking treatment for chronic rhinitis symptoms of at least 6 months duration and willing to undergo an office-based procedure~5. Moderate to severe symptoms of rhinorrhea (rTNSS rating of 2 or 3 for rhinorrhea)~6. Mild to severe symptoms of nasal congestion (rTNSS rating of 1, 2 or 3 for congestion)~7. rTNSS score of greater than or equal to 6~8. Dissatisfaction with medical management, defined as usage of intranasal steroids for a minimum of 4 weeks without adequate symptom relief, as judged by the subject~Exclusion Criteria:~1. Anatomic obstructions that in the investigator's opinion limit access to the posterior nose~2. Altered anatomy of the posterior nose as a result of prior sinus or nasal surgery or injury~3. Active nasal or sinus infection~4. Moderate to severe ocular allergic symptoms (such as eye tearing \[epiphora\], itching \[pruritus\], or redness \[erythema\])~5. History of significant dry eye~6. History of any of the following: nose bleeds in the past 3 months, rhinitis medicamentosa, head or neck irradiation~7. Known or suspected allergies or contraindications to the anesthetic agents and/or antibiotic medications to be used during the study procedure session~8. Known or suspected to be pregnant, or is lactating~9. Participating in another clinical research study~10. Other medical conditions which in the opinion of the investigator would predispose the subject to poor wound healing, increased surgical risk, or poor compliance with the requirements of the study

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- InSeca Stylus Treatment Group (Type: EXPERIMENTAL): Subjects treated with low power radiofrequency energy applied to the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab for Primary Pterygium Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with primary pterygium~Exclusion Criteria:~* Patients with diabetes mellitus~* collagenopathies,~* previous ocular surgeries,~* pregnant or lactating patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- One subconjunctival injection (Type: EXPERIMENTAL): Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery
- Two subconjuctival injections (Type: EXPERIMENTAL): Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery
- Conventional treatment (Type: ACTIVE_COMPARATOR): Autoconjunctival grafting without subconjuntival bevacizumab injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 18 years or older at time of screening~* Has moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on FWS) as determined by in-clinic assessments by both the investigator and the subject(where: 0= 'none', 1= 'mild', 2= 'moderate', 3= 'severe').~Exclusion Criteria:~* Any medical condition that may place the subject at increased risk due to exposure to botulinum toxin, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, profound atrophy or weakness in the target muscles, or any other condition (at the investigator's discretion) that might interfere with neuromuscular function or contraindicate botulinum toxin therapy.~* Previous treatment with any serotype of botulinum toxin for any indication within the 12 months prior to screening, or any planned treatment with botulinum toxin of any serotype for any reason during the trial (other than the investigational treatment).~* Active skin disease/infection or irritation at the treatment area.~* Pregnant, breastfeeding or planning to become pregnant during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Botulinum toxin A (Type: EXPERIMENTAL): Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into glabellar area.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
- Botulinum toxin A open label extension phase (Type: EXPERIMENTAL): Open Label Extension Phase for all Subjects of Arm 1 and 2 for up to 3 treatment cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone and Glucose Metabolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>18 years old.~* Severe GH deficiency as diagnosed by an inadequate GH stimulation in three different tests:~  1. peak response \< 3 µg/l during an insulin tolerance test;~ 2. \< 3 µg/l during glucagon test;~ 3. \< 9 µg/l during GHRH-arginine stimulation test).~Exclusion Criteria:~* GH replacement therapy prior to inclusion.~* History of diabetes Type 1 or 2.~* Biochemical evidence of impaired hepatic or renal function.~* History of cardiovascular disease.~* Uncontrolled hypertension.~* Current inflammatory or malignant disease.~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Growth Hormone (Type: EXPERIMENTAL): Therapy with recombinant human GH (Genotropin® 1 mg = 3 IU, Pfizer Inc., NY, USA) daily by subcutaneous injection using a Genotropin pen at maximal GH dose of 0.003 mg/kg/day in patients with severe GHD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Two Tetanus Toxoid Vaccination Strategies: Cold Chain Versus Controlled Temperature Chain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged between 14 to 49 years of age~* Living in the district of Moïssala, Chad~* Have no proof of previous vaccination or previous vaccination is not greater than 1 dose of vaccine~* Previous dose received more than 1 month before~* Consented to be included in the study~Exclusion Criteria:~* Allergic reaction to previous tetanus vaccination~* Severe febrile illness~* Have received a tetanus vaccine within the previous month~* Refuses vaccination or does not consent~* Nomadic population travelling before the end of the study~* Pregnant women due to deliver within 2 weeks

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Cold chain (Type: ACTIVE_COMPARATOR): Group vaccinated with tetanus toxoid vaccine kept in cold chain
- CTC (Type: EXPERIMENTAL): Group vaccinated with tetanus toxoid vaccine kept in controlled temperature chain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Imipramine in Treatment of Refractory Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients fulfill the diagnostic criteria of functional dyspepsia as defined by Rome II criteria~* Age \> 18 years old~* Failure of treatment response to PPI, H2 receptor antagonist fo 8 weeks and domperidone for 4 weeks~Exclusion Criteria:~* Organic pathology detected by endoscopy~* GERD or IBS as dominant compliant~* Presence of any alarm symptom: anemia, recurrent vomiting, weight loss~* Concomitant Helicobacter pylori infection~* Concomitant use of neuroleptic or antidepressant, NSAID~* Previous gastrointestinal surgery~* Cardiac arrhythmia, untreated glaucoma or benign prostate hypertrophy~* Pregnancy~* Known hypersensitivity or contraindication for tricyclic antidepressant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imipramine (Type: ACTIVE_COMPARATOR): Imipramine 25mg nocte for first 2 weeks then Imipramine 50 mg nocte for 10 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1 tablet for first 2 weeks then Placebo 2 tablets for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete